INFORMATION FOR
News
Teplizumab is a type of antibody therapy. It blocks T cells, the ’attack dogs’ of the immune system, stopping them destroying insulin-producing islet cells in the pancreas. A 76-person study — which ran from 2011 to 2018 — found that people who received the treatment developed diabetes symptoms after about five years, on average. That’s three years longer than the average delay for those who received the placebo. It’s also the first drug proven to delay the onset of an autoimmune disorder. The drug's development provides a roadmap for the discovery of pharmaceuticals to stall or prevent other conditions, including rheumatoid arthritis and multiple sclerosis.
Scientists say a mild Covid infection increased immune benefits from a later flu vaccine, but with a biological twist.
Two Yale labs will lead projects, in collaboration with other leading universities, tasked with developing new approaches to understand and combat pathogens.
The ‘tripledemic’ unfolding this winter is one of several odd trends among respiratory virus infections these last years. Viruses, it turns out, can block one another and take turns to dominate.
Joseph Craft, MD, Paul B. Beeson Professor of Medicine (Rheumatology) and professor of immunobiology has been awarded the 2022 Distinguished Innovator Award by The Lupus Research Alliance (LRA).
Yale Cancer Center's Class of 1961 Cancer Research Awards were presented to Nikhil Joshi, PhD, and Kurt Schalper, MD, PhD, at the annual Yale Cancer Center Conclave on January 5, 2023.
Yale Cancer Center’s Annual Conclave was held on January 5, 2023 to recognize scientific and clinical accomplishments of the Center's faculty and staff in 2022. Dr. Eric Winer hosted the event and presented research awards in four categories.
A new study finds that COVID-19 can trigger stronger inflammatory responses in males, resulting in changes to their functional immunity long after recovery.
A new Yale-led study finds that testing for a single immune system molecule on nasal swabs can help detect stealthy viruses not identified in standard tests.
A new FDA-approved drug delays the onset of type 1 diabetes and the need for insulin injections for several years.
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
We talk a lot about the role that physician-scientists play as “interpreters” and “translators” between the worlds of medicine and research. But that often means stepping outside of one’s narrow area of scientific expertise to help colleagues and trainees understand clinically relevant data that informs patient care, even if it’s far from what you look at in your own research.
Researchers from the Yale School of Medicine Section of Cardiovascular Medicine outline emerging areas of research in cardiovascular medicine. Explore the latest advances in scholarly and scientific publishing.
With a WHRY grant, Dr. Lauren Sansing is exploring the response of brain cells to stroke in aging women.
Antidepressants can increase the risk of preterm birth, but it’s unclear why. A new Yale study shows inflammation may play a key role.
Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.
The 2022 Yale Life Science Pitchfest held on December 8, 2022 featured 31 Yale faculty innovators presenting breakthrough research projects in therapeutics, medical devices, and digital health to a crowd of over 325 people from 120+ companies, including 14 industry judges.
Rong Fan, PhD, has made significant contributions to biotechnology innovation and precision medicine, particularly in the field of single-cell & spatial omics and cancer immunotherapy.
A new medication for type 1 diabetes delays onset of the disease.